883901-68-6

Basic information

• Product Name: 5-bromo-2-ethenylpyrimidine
• Synonyms: 5-bromo-2-ethenylpyrimidine;5-Bromo-2-vinylpyrimidine
• CAS NO: 883901-68-6
• Molecular Formula: C6H5BrN2
• Molecular Weight: 185.03
• Mol File: 883901-68-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2-ethenylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-ethenylpyrimidine(883901-68-6)
• EPA Substance Registry System: 5-bromo-2-ethenylpyrimidine(883901-68-6)

Safety Data

• Hazardous Substances Data: 883901-68-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-2-ethenylpyrimidine is used as a building block for the synthesis of various biologically active compounds. Its unique structure allows it to be a potential candidate for drug development, particularly in the area of antiproliferative and anticancer activities.
Used in Organic Synthesis:
5-bromo-2-ethenylpyrimidine is used as a reagent in chemical reactions for the synthesis of a wide range of biologically active compounds. Its presence of a bromine atom and an ethenyl group makes it a valuable component in the creation of new molecules with potential therapeutic applications.
Overall, 5-bromo-2-ethenylpyrimidine plays an important role in medicinal chemistry and organic synthesis due to its diverse applications and the potential for developing new drugs and therapeutic agents.

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 75927-49-0 pinacol vinylboronate 
• 183438-24-6 5-bromo-2-iodopyrimidine 
• 1826-67-1 vinyl magnesium bromide 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 32779-37-6 2,5-dibromopyrimidine 

Relevant articles and documents

PYRIDAZINE DERIVATIVES AS RORC MODULATORS

Compounds of formula (I): (I) or pharmaceutical salts thereof, wherein m, n,, p, q A, B, Ri, R2, R3, R4, R5, R6and R7are as defined herein. Also disclosed are methods of making the compounds and using the compounds as RORs modulators for treatment of inflammatory diseases such as arthritis.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

Provided is a sulfonamide derivative represented by the following general formula (1) and having an α4 integrin inhibitory effect with high selectivity with a low effect on α4β1 and a high effect on α4β7, or a pharmaceutically acceptable salt thereof (in the general formula (1), A, B, D, E, R41, and a to h are as described in the description).

HETEROARYL OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES

The invention relates to compounds of Formula (I) wherein X, Y, R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors

A series of dual-targeting, alcohol-containing benzothiazoles has been identified with superior antibacterial activity and drug-like properties. Early lead benzothiazoles containing carboxylic acid moieties showed efficacy in a well-established in vivo model, but inferior drug-like properties demanded modifications of functionality capable of demonstrating superior efficacy. Eliminating the acid group in favor of hydrophilic alcohol moieties at C 5, as well as incorporating solubilizing groups at the C7 position of the core ring provided potent, broad-spectrum Gram-positive antibacterial activity, lower protein binding, and markedly improved efficacy in vivo.

Antibacterial Compounds

The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the invention pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR

The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6- alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- -membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.